Position statement on radiopharmaceutical production for clinical trials

The EU regulation 536/2014 aims to facilitate the experimental use of diagnostic radiopharmaceuticals in particular for GMP requirements and needs to be applied in EU countries. As definitely clarified by this survey, the application is still far from being completed due to national restrictions tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bormans, G., Buck, A., Chiti, A., Cooper, M., Croasdale, J., Desruet, M., Kumar, V., Liu, Y., Penuelas, I., Rossetti, C., Schiavo, R., Schwarz, S. W., Windhorst, A. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Position Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824698/
https://www.ncbi.nlm.nih.gov/pubmed/29503853
http://dx.doi.org/10.1186/s41181-017-0031-y
Descripción
Sumario:The EU regulation 536/2014 aims to facilitate the experimental use of diagnostic radiopharmaceuticals in particular for GMP requirements and needs to be applied in EU countries. As definitely clarified by this survey, the application is still far from being completed due to national restrictions that are conflicting with the content of the above EU regulation. Although the nuclear medicine centers are obliged to be compliant with national regulatory, national authorities have to be required to work towards full application of the regulation. On the other hand, an update of 536/2014 that includes therapeutic radiopharmaceuticals would also be beneficial to a rational and safe advance of nuclear medicine.

Ejemplares similares